Products with Central nervous system depressant action Bioactivity

Explore BioCrick products associated with Central nervous system depressant action biological activity, including catalog numbers, product names and available bioactivity information.

Cat. No.	Product Name
BCN5080	Strictosamide
1. Strictosamide may have important effects on inflammation and inflammatory pain. 2. Strictosamide is slightly toxic to Charles River mouse (LD(50)=723.17 mg/kg), producing CNS depression and kidney toxicity. 3. Strictosamide has nonsignificant in vitro and in vivo effect on kidney Na(+),K(+)-ATPase activity but produced an in vivo increase of Na(+),K(+)-ATPase activity of brain. 4. Strictosamide possesses antibacterial and antiviral activities.
BCN5273	Gardneramine
1. Gardneramine and hirsutine show a local anesthetic action, they also can inhibit the ganglionic transmission of the dog urinary bladder and that the blockade of the nicotinic receptor plays a main role. 2. Gardneramine has a mild central depressive effect.
BCN5298	Mesuaxanthone A
1. Mesuaxanthone A and mesuaxanthone B are two yellow pigments. 2. Mesuaxantbone A and mesuaxanthone B produce varying degrees of C.N.S. depression characterised by ptosis, sedation, decreased spontaneous motor activity, loss of muscle tone, potentiation of pentobarbitone sleeping time and ether anaerthesia in mice and rats; they also exhibit anti inflammatory activity both by intraperitoneal and oral routes in rats.
BCN5583	Reticuline
Reticuline is a key compound in the biosynthetic pathway for isoquinoline alkaloids in plants, which include morphine, codeine and berberine. Reticuline possesses potent central nervous system depressant action, it (50-100 mg/kg i.p.) can produce alteration of behaviour pattern, prolongation of pentobarbital-induced sleep, reduction in motor coordination and D-amphetamine-induced hypermotility and suppression of the conditioned avoidance response. (S)-Reticuline can elicit vasorelaxation probably due to the blockade of the L-type voltage-dependent Ca(2+) current in rat aorta, the effect may contribute to the potential cardioprotective efficacy of (S)-reticuline.
BCN6706	Yangambin
1. Yangambin is a selective antagonist of the cardiovascular effects of platelet activating factor (PAF) and therefore constitutes a potential therapeutic agent in different shock states where abnormal PAF release is supposed to play an important role. 2. Yangambin has central nervous system activity, it presents a depressant activity in the open field, forced swimming and pentobarbital sleeping time tests. 3. Yangambin has hypotensive effect, which is probably due to a peripheral vasodilatation that involves, at least, the inhibition the Ca2+ influx through voltage-gated Ca2+ channels.

Central nervous system depressant action Bioactivity Products